The death of a participant in a clinical trial of an antibody treatment for Alzheimer's disease, which is now under consideration by the US Food and Drug Administration, may be linked to the experimental drug, a new report shows.The research letter, published Wednesday in the New England Journal of Medicine, shares details about what happened to the participant in the open-label extension phase of the trial of lecanemab.
#years #essentially #researchers #combination #expectations #participants #consideration #participant #asymptomatic #blood-pressure
[
add
]
[
|
|
...
]